The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), Johnson & Johnson (Gold), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | Major breakthroughs in leukemia treatment: precision therapy and immunotherapy
Iskra Pusic, MD, MSCI, Washington University School of Medicine, St. Louis, MO, discusses major breakthroughs in leukemia treatment, highlighting the shift from conventional chemotherapy to precision therapies targeting specific molecular and genetic abnormalities. Prof. Pusic highlights immunotherapy as another major breakthrough, reviewing the growing role of CAR T-cell therapy and bispecific antibodies in relapsed/refractory disease across a range of leukemia subtypes. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I mean there have been a lot of major breakthroughs in the last five to ten years and in a way the field has moved towards like broadly administering chemotherapy drugs to a much more targeted approach where now we target molecular profiles, genetic mutations of leukemic cells and have much more precise treatments. And the other things are immunotherapies such as CAR T-cells, such as bispecific therapies, and those have been primarily important for people with relapsed and refractory diseases who otherwise might not have had any real viable treatment approaches that now can be cured with this treatment...
I mean there have been a lot of major breakthroughs in the last five to ten years and in a way the field has moved towards like broadly administering chemotherapy drugs to a much more targeted approach where now we target molecular profiles, genetic mutations of leukemic cells and have much more precise treatments. And the other things are immunotherapies such as CAR T-cells, such as bispecific therapies, and those have been primarily important for people with relapsed and refractory diseases who otherwise might not have had any real viable treatment approaches that now can be cured with this treatment. So I think these have been major breakthroughs and there are currently multiple clinical trials testing these different approaches in patients with all kinds of leukemias, acute, chronic, myeloid, lymphoid, so I think this has really advanced the field significantly.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
